WHO updates ART guidelines

The update can be accessed here.

Dolutegravir is now recommended as first line therapy for all, including women of child bearing potential, based on increasing rates of transmitted NNRTI resistance and reduced estimates of risk for neural tube defects. Efavirenz 400 mg has replaced 600 mg as a preferred alternative regimen.